Edwards Lifesciences (EW) PT Lowered to $70 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- SanDisk shares fall on election and chip sector pressure
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
TD Cowen Downgrades Edwards Lifesciences (EW) to Hold
July 25, 2024 7:17 AM EDTTD Cowen analyst Joshua Jennings downgraded Edwards Lifesciences (NYSE: EW) from Buy to Hold with a price target of $70.00 (from $100.00).
The analyst comments "We are downgrading EW to Hold as we are now forecasting HSD revenue growth in 2024 and 2025 due to... More
Edwards Lifesciences (EW) PT Lowered to $85 at RBC Capital
July 25, 2024 6:32 AM EDTRBC Capital analyst Shagun Singh lowered the price target on Edwards Lifesciences (NYSE: EW) to $85.00 (from $101.00) while maintaining a Outperform rating.
The analyst comments "EW delivered Q2'24 results missing sales expectations and lowering 2024 operational revenue growth outlook to 8-10%... More
Edwards Lifesciences (EW) PT Lowered to $76 at Evercore ISI
July 25, 2024 4:59 AM EDTEvercore ISI analyst Vijay Kumar lowered the price target on Edwards Lifesciences (NYSE: EW) to $76.00 (from $91.00) while maintaining a In Line rating.
The analyst comments "Thesis Update: This was tough call for EWthe rev miss, low quality EPS (~5c aid from discrete... More



